ARQT股票表现 - Arcutis Biotherapeutics, Inc. (ARQT)上周收盘价为$10.66，过去四周上涨了14.6%[1] - 分析师的平均目标价为$16.50，显示了54.8%的上涨潜力[1] - 分析师对ARQT的短期目标价存在较大差异，最低估值为$8，最乐观估值为$26[2] ARQT盈利前景 - 分析师普遍认为ARQT将会报告比之前预期更好的收益[4] - 分析师对ARQT的目标价存在较高的一致性，这可能是进一步研究的良好起点[7] - 分析师对ARQT的盈利前景持续乐观，这可能是股票上涨的合理理由[9] ARQT投资建议 - 研究表明，分析师设置的目标价往往会误导投资者，而不是指导他们[5] - 分析师通常会设置过于乐观的目标价，以激发对公司股票的兴趣[6] - 投资者不应完全忽视目标价，但也不应仅凭此做出投资决策[8] ARQT其他信息 - 过去30天，ARQT当前年度的Zacks共识估值增长了6%[10] - ARQT目前具有Zacks排名2（买入），这是股票潜在上涨的更有力指标[11]

Arcutis Biotherapeutics, Inc.在美国皮肤科学会年会上展示的新数据 - Roflumilast cream 0.05%在2至5岁儿童中表现出显著改善，包括在第1周就达到了多个有效性终点[1] - 研究结果显示，使用roflumilast cream 0.05%的儿童中，39.4%在第4周达到了EASI-75的75%改善[2] - roflumilast cream 0.05%在治疗特应性皮炎方面表现出一致的有效性和良好的安全性和耐受性[3]

Findings show that seborrheic dermatitis is a unique inflammatory skin disease with its own molecular signature Suggests skin barrier disruption in seborrheic dermatitis is distinct with its own disease-specific pattern SAN DIEGO, Calif., March 09, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, highlights new research that, for the first time, reveals the gene expression pr ...

WESTLAKE VILLAGE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the closing of its previously announced underwritten public offering of 18,157,895 shares of common stock at a public offering price of $9.50 per share, which includes 2,368,421 shares issued upon the exercise in full by the underwriters of their option to purchase additional s ...

ARQT股价表现 - Arcutis Biotherapeutics, Inc. (ARQT)上周收盘价为$10.28，过去四周上涨了54.8%[1] - 分析师的平均目标价为$16.33，显示了58.9%的上涨潜力[1] - 分析师对ARQT的短期目标价范围从$6到$38不等，标准偏差为$12.09[2] 分析师观点 - 分析师普遍认为ARQT的盈利将好于他们之前的估计[4] - 研究表明，分析师设定的目标价很少能准确指示股票价格的走向[5] - 分析师往往设定过于乐观的目标价，这可能是为了提高与公司的关联或利益[6] 投资建议 - 尽管投资者不应完全忽视目标价，但仅基于目标价做出投资决策可能会导致令人失望的投资回报率[8] - ARQT近期的盈利前景引起了分析师的乐观情绪，这可能是预期股价上涨的合理理由[9] 其他观点 - Zacks对今年的预期估计在过去一个月内增加了3.2%，目前有一个买入评级[10] - ARQT目前拥有Zacks Rank 2 (Buy)，这是对股票短期潜在上涨的更有力指示[11]

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Arcutis Biotherapeutics, Inc. (ARQT) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Arcutis Biotherapeutics, Inc. is a member of our Medical group, which includes 1067 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Secto ...

WESTLAKE VILLAGE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the TD Cowen 44th Annual Health Care Conference. Details for the company’s participation are as follows: Fireside Chat Date: Monday, March 4, 2024 Fireside Chat Time: 2:10 pm ET The webcast for this conference may be accessed at the ...

公司介绍 - Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)是一家专注于开发免疫皮肤病领域有意义创新的商业阶段生物制药公司[1] - Arcutis拥有多个临床项目，涵盖多种炎症性皮肤病，包括头皮和身体银屑病、特应性皮炎和斑秃症[3] 参会信息 - Arcutis将参加TD Cowen第44届年度医疗保健大会的炉边聊天，具体时间为2024年3月4日下午2:10 ET[2] 前瞻性声明 - 公司的新闻稿和即将进行的炉边聊天讨论包含“前瞻性”声明，提到了Arcutis解决紧急需求的潜力和数据和监管事件时间的期望[4]

WESTLAKE VILLAGE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritten public offering of common stock. Arcutis is selling 15,789,474 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $9.50 per share. All shares of common stock to be sold in the offering a ...

WESTLAKE VILLAGE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the commencement of an underwritten public offering of $150.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants in this o ...